Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives $13.20 Average Target Price from Analysts

Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Free Report) have earned a consensus rating of “Moderate Buy” from the five ratings firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year […]

Related Keywords

Switzerland ,Swiss , ,Seres Therapeutics Company Profile ,Blackrock Inc ,Metlife Investment Management ,York Mellon Corp ,Seres Therapeutics Inc ,Swiss National Bank ,Jpmorgan Chase Co ,Nasdaq ,Seres Therapeutics ,Get Free Report ,Marketbeat Ratings ,National Bank ,New York Mellon Corp ,Life Investment Management ,Get Free ,Seres Therapeutics Daily ,Nasdaq Mcrb ,Mcrb ,Medical ,Ratings ,Consensus ,